Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: A virtual screening study

Kayhan Bolelli a,b,c, Tugba Ertan-Bolelli a,b, Ozan Unsalan d,e, Cisem Altunayar-Unsalan e

a Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 06560, Ankara, Turkey
b Bolelli Lab LLC, Stone Mountain, GA 30083, USA
c Lumitabs, Ulus, Ankara, 06610, Turkey
d Ege University, Faculty of Science, Department of Physics, 35100, Bornova, Izmir, Turkey
e Ege University, Central Research Testing and Analysis Laboratory Research and Application Center, 35100, Bornova, Izmir, Turkey

ARTICLE INFO
Article history:
Received 25 June 2020
Revised 19 September 2020
Accepted 12 October 2020
Available online 13 October 2020

Keywords:
COVID-19
Dobutamine
Drug discovery
Fenoterol
Molecular docking
Virtual screening

ABSTRACT
Global health is under heavy threat by a worldwide pandemic caused by a new type of coronavirus (COVID-19) since its rapid spread in China in 2019 [1]. Currently, there are no approved specific drugs and effective treatment for COVID-19 infection, but several available drugs are known to facilitate tentative treatment. Since drug design, development and testing procedures are time-consuming [2–5], virtual screening studies with the aid of available drug databases take the initiative at this point and save the time. Besides, drug repurposing strategies promises to identify new agents for the novel diseases in a time-critical fashion. In this study, we used structure based virtual screening method on FDA approved drugs and compounds in clinical trials. As a result of this study we choose three most prominent compounds for further studies. Here we show that these three compounds (dobutamine and its two derivatives) can be considered as promising inhibitors for SARS-CoV-2 main protease and results also demonstrate the possible interactions of dobutamine and its derivatives with SARS-CoV-2 main protease (6W63) [6]. Our efforts in this work directly address current urgency of a new drug discovery against COVID-19.

© 2020 Elsevier B.V. All rights reserved.

1. Introduction

Coronaviruses (CoVs) are known to cause mainly respiratory and enteric diseases in humans and animals [7]. They are classified into four genera, alpha, beta, gamma and delta-CoV [8]. As of June 25th, 2020, this newly emerged virus has spread to almost all countries with almost 9,494,571 confirmed cases and over 484,155 global deaths [9]. Currently, very limited information is known about the action mechanism and biology of COVID-19 and there is no vaccine or effective antiviral treatment against COVID-19, yet. Action mechanism of COVID-19 is still a mystery itself, but it was reported that it has the same cell-entry receptor, ACE2 (Angiotensin-Converting Enzyme 2), for infection as SARS-CoV [10,11]. On the other hand, there are growing number of 3D protein structures for COVID-19, generally related to the main protease structure resolved by mostly X-ray diffraction crystallography, available in Protein Data Bank (RCSB PDB).

Previous studies highlighted the importance of drug repurposing studies for certain types of diseases including, Parkinson’s, Alzheimer’s and Ebola [12–16]. Virtual screening research would replace the time-consuming efforts in identification of new targets for the existing drug molecules as demonstrated in earlier articles [17–19]. It is quite efficient to apply computer-aided drug design techniques to quickly identify promising candidates, especially after the detailed 3D-structures of key virus proteins are resolved. Taking the advantage of a recently deposited crystal structure of SARS-CoV-2 main protease enzyme (Mpro) in complex with its natural inhibitor [6], we used virtual screening approach. Structure of the natural ligand (X77) of SARS-CoV-2 main protease (Protein Data Bank (PDB) ID: 6W63) is given in Fig. 1.

Dobutamine (DBT) [1,2-Benzenediol, 4-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-(±)] is a beta-1 adrenergic agonist and was first developed as a structural analogue of isoprenaline [20]. DBT revealed that during the early stage of septic shock-induced ARDS, DBT treatment indicated a beneficial effect by relieving pulmonary edema in patients [21]. DBT was also shown to be effective for renal function parameters and it was well tolerated and elicited few side effects, thus, DBT appears to be used safely [22]. Moreover, it acts directly to increase myocardial
contractility [20] and DBT infusion is generally associated with decreases in pulmonary artery pressure and pulmonary capillary wedge pressure [20,22]. To the best of our knowledge there is no virtual screening study on DBT that inhibits 6W63.

Fenoterol (FNT) [1,3-Benzenediol, 5-(1-hydroxy-2-(2-(4-hydroxyphenyl)-1-methylamino)ethyl)-] is known a beta-2 adrenergic agonist drug [23]. In a very recent study performed on the relaxing effect of FNT on the contractions of horse isolated bronchi revealed that, FNT was found to be significantly more effective with respect to clenbuterol [24]. Bernasconi et al. showed that FNT is a rapid, powerful, but short-acting bronchodilator [25]. An evaluation of the clinical efficacy by FNT and salbutamol in horses with asthma could be of great interest to assess if they could represent more effective bronchodilators compared to clenbuterol [24]. Up to our knowledge, there is no docking study of FNT into SARS-CoV-2 MPro (6W63).

2. Methodologies

Structure-based virtual screening method focuses on the therapeutic targets 3D information. Docking procedures are used for the purpose of selecting the hits that exhibit chemical, structural and electronic characteristics. The information of the target protein can be derived from in silico technique or experimental data. We performed docking calculations and ADME properties predictions by Schrödinger 2020 software, with Maestro 12.2 and the Glide and QikProp modules [26–29].

2.1. Structure based virtual screening

X-ray crystallographic structure of SARS-CoV-2 MPro and its non-covalent inhibitor (X77) complex (PDB: 6W63) was retrieved from Protein Data Bank (www.rcsb.org) and prepared for docking process. In order to prepare the enzyme, we used the protein preparation wizard module. We chose OPLS-2005 force field for minimization and pH = 7.0 to minimize hydrogen bonds. Bond orders were assigned, with zero order bonds to disulfide bonds and metals as well. For virtual screening study, approximately 9,000 commercially available compounds (FDA approved drugs and compounds in clinical trials) were taken from ZINC database [30,31]. All these ligands were prepared by using Schrödinger, LigPrep module [26]. The bond angles and bond orders were assigned after ligand minimization step. In order to keep the ligands in the right protonation state in biological conditions, epik option was used. After the preparation of ligands and enzyme, we generated the grid for docking process. The active site of SARS-CoV-2 MPro was defined for generating the grid in Maestro. The grid box was limited to the size of 10 Å at the active site. First, docking procedure was validated by extracting the nature ligand, X77 from the binding site and re-docking it to SARS-CoV-2 MPro by using the Glide SP (standard precision glide docking) module [27,28]. Glide generates conformations internally and passes these through a series of filters. Glide had successfully reproduced the experimental binding conformations of X77 in SARS-CoV-2 MPro with an acceptable root-mean-square deviation (RMSD) value of 0.678 Å. Docking studies were carried out using high throughput virtual screening (HTVS) option, standard- precision (SP screening) and extra-precision (XP screening) mode of Glide module respectively. We considered ring conformations, nitrogen inversions, input partial charges and, for amides, a penalty for nonplanar conformations was applied. Epik state penalties were added to docking scores. We did not use any similarities or constraints for the docking calculations. The compounds were re-docked via post processing. The best pose was output based on Glide score. After visual inspection, we retained FNT and DBT together with one isomer of FNT as two potential inhibitor candidates. Docking scores of FNT and DBT, plus one isomer of FNT, and natural ligand were shown in Table 1.

2.2. ADME/Tox analysis

In order to obtain an efficient collection of hit molecules, in silico ligand filtration was also done for screening compounds by employing Lipinski “Rule of Five” [32] and ADME properties using QikProp module of Schrödinger Software [26]. Calculated ADME properties predictions of the selected hit compounds were shown in Table 2. This analysis includes, brain/blood partition coefficient (QPlog BB), aqueous solubility (QPlog S), total solvent accessible surface area (SASA), octanol/water partition coefficient (QPlog
Docking scores and QikProp Properties Predictions of all candidate compounds are shown in Table 1 and 2, respectively. According to docking results, docking scores of all three compounds were found between −9.467 and −8.845. We found that FNT-SS and FNT-RS have same docking scores and these values are better than X77. DBT seemed to have higher docking score (−8.845) than X77 (−8.938). Almost all the pharmacokinetic properties conducted by QikProp were within acceptable range. Three top compounds are with good inhibiting profile and exhibit suitable ADME/Tox (toxicity) properties for SARS-CoV-2 M\(^{pro}\). To the best of our knowledge, there are not any docking studies on FNT (SS and RS) for inhibition purpose of COVID-19 structure (6W63), although they are approved by FDA. In our opinion, these candidates need to be rapidly confirmed whether they might be used as a drug against COVID-19.

After we figured out that natural ligand of SARS-CoV-2 M\(^{pro}\) showed H-bond with Asn142, Gly143, His163 and Glu166 in active site, we next evaluated our docking results and found similarity that all three compounds showed H-bonds with His163, and Glu166 which are the important residues for the SARS-CoV-2 M\(^{pro}\) inhibition. Our findings revealed that DBT interacts via H-bonds towards Phe140, His163, Glu166, π−π interaction with His41. Besides, FNT-SS showed H-bonds towards His163 and Glu166 and water mediated H-bond with Asn142 whereas FNT-RS showed H-bonds with His163 and Glu166 and a π−cation interaction His41 (Fig. 3). From docking results, we determined that our hit compounds are in strong interactions with SARS-CoV-2 M\(^{pro}\) and particularly FNT-SS and -RS showed stronger interactions the than X77, natural ligand. Docking scores of both FNT-SS and -RS are −9.467 and this is better than docking score of X77 (Table 1). Thus, both FNT compounds might be promising inhibitors of SARS-CoV-2 M\(^{pro}\).

Next, we investigated, pharmacokinetic properties of these prominent compounds by performing QikProp Properties Predictions which was implemented in Schrödinger software with the recommended values and range. Based on these predictions, the human oral absorption percentage of DBT was found to be ~74%. However, FNT-SS and RS showed medium range oral absorption with the value of ~58-63%. For tested inhibitor candidate compounds, the partition coefficient (QPlog P<sub>o/w</sub>) was within the recommended range of 0.86-2.47. Brain/blood partition coefficient (QPlog BB) and total soluble accessible surface area (SASA) were also found to be within satisfactory range. Violations of Lipinski’s “Rule of Five” were also calculated and none of the compounds violate this rule, thus indicating their potential as drug-like molecules [32,33]. Additionally, DBT is in the acceptable range for predicted apparent Madin-Darby canine kidney (MDCK) cell permeability (QPMDCK) value of 28.362 whereas FNT-SS (23.431) and -RS (9.784) exhibit poor mimic for permeability in blood-brain barrier compared to DBT. Here, QPMDCK is predicted apparent MDCK cell permeability in nm/s and poor means <25 and great means >500 [22]. Predicted aqueous solubility values (QPlog S) were also found as acceptable. QikProp pharmacokinetic properties predictions of the hit compounds were presented in Table 2.
4. Discussion

This global threat showed that our current options against this virus are quite limited. Even though there are increasing number of efforts, no drugs can treat effectively this virus currently. Discovering a broad-spectrum drug(s) that may be used for COVID-19 is still a challenging marathon. Given the fact that drug development and registration progress is time-consuming, drug repurposing against COVID-19 and other diseases is the quickest way to open the way towards treatment for such infectious diseases.

In order to contribute to discovery of potential COVID-19 drugs as soon as possible, we first screened thousands of compounds and extracted two main structures, FNT (SS and RS) and DBT for one certain SARS-CoV-2 MPro (6W63). Docking results revealed that
X77 was seen to be H-bonded via Gly143, His163, Glu166 in active site of the protein. Similarly, all hit compounds showed H-bonds with His163, and Glu166, which are the important residues for the SARS-CoV-2 MPro (Fig. 3). Based on our docking work, DBT and FNT are in strong interactions with the enzyme and we figured out that FNT-SS and RS interacted with main protease stronger than natural ligand, with the docking score of -9.467 which is better than X77’s docking score of -8.938. Here, we propose that, particularly FNT-SS and RS can be considered as the best two SARS-CoV-2 MPro inhibitors rather than DBT. Although the docking score of DBT is higher than the X77, meaning not better than any of FNT isomers, it still can be considered as a potential treatment against COVID-19 since it also has a close docking value to X77.

It would only be possible to use all these compounds after clinical tests are complete and the simulation results are validated. Moreover, since there are much more crystallographic structures of this virus, increasing daily, it is important to focus on new crystallographic structures of COVID-19 together with their natural ligands in order to further understand its action mechanism and nature.

Even though our calculations demonstrated that FNT-SS and RS inhibit COVID-19 better, further computational, experimental and clinical research should be performed. Most importantly, since there is still no effective drug and vaccine against this virus, we suggest that our results open up a new direction for further research on the way to design new potential drugs, specifically like FNT and DBT, against COVID-19.

5. Conclusion

COVID-19 is now a global concern and since there is a lack of proper and effective medication, it is urgent and necessary to find and evaluate treatment methods more rapidly. At this step, computational methods play a crucial role and they pave the way to find leading candidate compounds to be used as drugs for COVID-19 as well as other diseases. Here, we used virtual screening techniques and identified three FDA approved hits as potential inhibitors for 6W63, SARS-CoV-2 main protease enzyme, by using extensive ZINC database. Based on molecular docking approach in our work, dobutamine and fenoterol would be possible candidates against COVID-19. We have obtained satisfactory results providing that natural ligand X77 and two possible ligands, dobutamine and fenoterol, exhibit inhibition on SARS-CoV-2 main protease enzyme (6W63). It was observed that the binding ability of dobutamine and fenoterol was better compared to natural ligand X77. We have been able to find that all our compounds fit at the active site of the 6W63 and showed hydrogen bonds with the surrounded amino acids in the cavity.

As a conclusion, these candidates could be promising inhibitors of SARS-CoV-2 MPro and they also need to be rapidly confirmed by experimental study. Besides, we suggest that the present findings can be led to design new and more potent drugs against COVID-19.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

CRediT authorship contribution statement

Kayhan Boletli: Data curation, Resources, Software, Visualization, Writing - original draft. Tugba Erkan-Boletli: Conceptualization, Data curation, Resources, Software, Visualization, Writing - original draft. Ozan Unsalan: Data curation, Funding acquisition, Software, Writing - original draft, Writing - review & editing. Cisem Altunayar-Unsalan: Conceptualization, Writing - original draft.

Acknowledgements

We acknowledge Rita Podzuna of Schrödinger for supplying one-month fully operational evaluation of Schrödinger suite.

References

[1] D.S. Hui, E.I. Azhar, T.A. Madani, F. Ntoumi, R. Kock, O. Dar, G. Ippolito, T.D. Mchugh, Z.A. Memish, C. Drosten, A. Zumla, E. Petersen, The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis. 91 (2020) 264–266.
[2] C.P. Adams, V.V. Brantner, Estimating the cost of new drug development: Is it really $802 million, Health Aff (2005) 420–428.
[3] J.A. DiMasi, M.I. Florez, S. Stergioupolus, Y. Peña, Z. Smith, M. Wilkinson, K.A. Getz, Development times and approval success rates for drugs to treat infectious diseases, Clin. Pharmacol. Ther. 107 (2020) 324–332.
[4] J.A. DiMasi, H.G. Grabowski, R.W. Hansen, Innovation in the pharmaceutical industry: New estimates of R&D costs, J. Health Econ. 47 (2016) 20–33.
[5] J.W. Scannell, A. Blankley, H. Boldon, B. Warrington, Diagnosing the decline in pharmaceutical R&D efficiency, Nat. Rev. Drug Discov. 11 (2012) 191–200.
[6] Structure of SARS-CoV-2 main protease bound to potent broad-spectrum non-covalent inhibitor X77, https://www wwpdb.org/pub/dpb/dbt_00006w63, 2020 (accessed 10 August 2020).
[7] P.S. Masters, S. Perlman, Fields Virology, E. Lippincott Williams & Wilkins, Philadelphia, 2013, pp. 825–858.
[8] International Committee on Taxonomy of Viruses Virus taxonomy. 2018.
[9] Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU), https://coronavirus.jhu.edu/map.html
[10] Y. Cao, L. Li, Z. Feng, S. Pan, P. Huang, X. Sun, F. Wen, X. Huang, G. Ning, W. Wang, Comparative genetic analysis of the novel coronavirus (2019-nCoV)/SARS-CoV-2 receptor ACE2 in different populations, Cell Discov. 6 (2020) 11.
[11] J.L. Chen, Pathogenicity and transmissibility of 2019-nCoV-a quick overview and comparison with other emerging viruses, Micr. Infect. 22 (2020) 671–671.
[12] J.P.F. Bai, C.W. Hsu, Drug repurposing for Ebola virus disease: principles of consideration and the animal rule, J. Pharm. Sci.-Us 108 (2019) 798–806.
[13] J. Athauda, T. Feltywine, Drug repurposing in Parkinson's disease, CNS Drugs 32 (2018) 747–761.
[14] W. Zheng, W. Sun, A. Simeonov, Drug repurposing screens and synergistic drug-combinations for infectious diseases, Brit. J. Pharmacol. 175 (2018) 181–191.
[15] K.Y. Yeongi, C. Law, Repurposing antihypertensive drugs for the management of Alzheimer's disease, Curr. Med. Chem. (2020) https://doi.org/10.2174/138920021666619112114223.
[16] K. Paban, S. Mondal, S. Bangash, A. Roy, J. Kordower, S. Dacarazhi, Repurposing maraviroc, an antiretroviral drug, for Parkinson disease, J. Neurovir. 24 (2018) 564.
[17] S. Durdagi, R.E. Salinas, M. Stein, M. Yurtsever, P. Seeman, Binding interactions of dopamine and apomorphine in D2High and D2Low states of human dopamine D2 receptor using computational and experimental techniques, ACS Chem. Neurosci. 7 (2016) 185–195.
[18] S. Durdagi, H.J. Duff, S.T. Noskov, Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the HERG pore domain, J. Chem. Inf. Model. 51 (2011) 463–474.
[19] D.L. Ma, D.S.H. Chan, C.H. Leung, Drug repositioning by structure-based virtual screening, Chem. Soc. Rev. 42 (2013) 2130–2147.
[20] E.H. Sonnenblick, W.H. Prishman, T.H. Lopetzel, Dobotamine: A new synthetic cardiovascular systeptic amine, Med. Intell. 300 (1979) 17–22.
[21] M. Zhou, J. Dai, M. Du, W. Wang, C.X. Guo, Y. Wang, R. Tang, F.L. Xu, Z.G. Rao, G.Y. Sun, Effect of dobutamine on extravascular lung water index, ventilator function, and perfusion parameters in acute respiratory distress syndrome associated with septic shock, Artif. Cell Nanomed. B (2016) 1326–1332.
[22] C.V. Leier, J. Webel, C.A. Bush, The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure, Circulation 56 (1977) 468–472.
[23] I. Zimmermann, A.A. Bugalhodealmeida, W. Wallenhorst, W.T. Ulmer, The mechanism of a Beta-2-receptor stimulating bronchodilating drug - study of fenoterol (Berotec) in allergic respiratory-tract obstruction in dogs hypersensitized to Ascaris-Suurn, Klin. Wochenschr. 58 (1980) 395–402.
[24] C. Pozzoli, S. Bertini, E. Poli, G. Placenza, A. Menozzi, Relaxing effects of clenbuterol, ritodrine, salbutamol and fenoterol on the contractions of horse isolated bronchi induced by different stimuli, Res. Vet. Sci. 128 (2020) 43–48.
[25] M. Bernasconi, R. Brandolese, R. Poggi, E. Manzin, A. Rossi, Dose-response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen-tension in mechanically ventilated patients with chronic airflow obstruction, Int. Care Med. 16 (1990) 108–114.
[26] Schrödinger LLC New York, USA: Schrodinger Inc. http://www.schrodinger.com. Schrödinger LLC New York, USA: Schrodinger Inc. http://www.schrodinger.com, 2018.
[25] R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, P.S. Shemkin, Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J. Med. Chem. 47 (2004) 1739–1749.

[26] R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, D.T. Mainz, Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, J. Med. Chem. 49 (2006) 6177–6196.

[27] C.A. Taft, C.H.T.P. Silva, Current state-of-the-art for virtual screening and docking methods, in: A., T. C. (Ed.), New Developments in Medicinal Chemistry, 2, Bentham Science Publishers Ltd., Sharjah, UAE, 2014, pp. 3–169.

[28] T. Sterling, J.J. Irwin, ZINC 15 – Ligand discovery for everyone, J. Chem. Inf. Model. 55 (2015) 2324–2337.

[29] J.J. Irwin, T. Sterling, M.M. Mysinger, E.S. Bolstad, R.G. Coleman, ZINC: a free tool to discover chemistry for biology, J. Chem. Inf. Model. 52 (2012) 1757–1768.

[30] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 64 (2012) 4–17.

[31] O Unsalan, H. Arı, C. Altunayar-Unsalan, K. Bolelli, M. Boyukata, I. Yalcin, FTIR, Raman and DFT studies on 2-[4-(4-ethylbenzamido)phenyl]benzothiazole and 2-[4-(4-nitrobenzamido)phenyl]benzothiazole supported by differential scanning calorimetry, J. Mol. Struct. 1218 (2020) 128454.